Stempeutics Research Bangalore is a late stage life science company focused on developing and commercializing novel therapeutics based on adult stem cells. It was incorporated by the Manipal Group in Jan 2006. Stempeutics strength lies in developing innovative stem cell based products by nurturing cutting edge research and clinical applications through dedicated efforts of its highly qualified team. Currently it is focusing on the following innovative products:
Company's flagship product is Stempeucel® drug. It is an on-demand, off-the-shelf product based on pooled, allogeneic Mesenchymal Stromal Cells derived from bone marrow of healthy, adult volunteers. Stempeucel® is being developed for the treatment of Critical Limb Ischemia (CLI) amongst other indications such as Osteoarthritis (OA) & Diabetic Foot Ulcer (DFU). In 2017 DCGI granted manufacturing & marketing approval for Stempeucel® product for the treatment of Non-Atherosclerotic CLI patients. Stempeucel® is also ready for Phase 3 Atherosclerotic CLI, Phase 3 OA and Phase 2 DFU. Stempeucel® has strong patent protection with 18 patent applications filed across the globe. The core Stempeucel® patent has been granted in USA, China, UK, Germany, France, Italy, Australia, New Zealand, South Africa, Japan, and Singapore. Stempeucel® has been classified as an ATMP product by EMA and designated as an Orphan Drug for the treatment of CLI due to Buerger's Disease by EMA
Another innovative product being developed by Stempeutics is Stempeucare® range of cosmetics. It is developed from adult stem cells derived Growth Factors/Cytokines cocktail for various derma applications including rejuvenation of aging skin, hair fall control & hair growth, under eye cream etc. First product which is being marketed in India is Cutisera™. Cutisera™ is an intensive firming skin care cosmetic product with multiple benefits. Other products in the pipe line are (a) Trichosera for anti-hair fall and hair re-growth (b) Optisera - an eye care product for reducing eye bags & dark circles and fine lines & wrinkles. Stempeutics is looking for strong, strategic partner to market these innovative products developed from Growth Factors/Cytokines secreted by adult stem cells
The third product Stempeutics is developing is Stempeutron™ medical device. It is a point-of-care, closed system, automated medical device for the isolation of stromal vascular fraction (SVF) cells from human adipose tissue for addressing the need in the broad field of regenerative medicine. Stempeutron is the first product to use novel robotic and filtration technology to isolate clinical grade SVF from adipose tissue. SVF has broad clinical utility in regenerative medicine for repair of diseased organs as well as in plastic and reconstructive surgery.
Scientists working at Stempeutics have filed over 57 patents and have published over 75 peer reviewed international publications. Stempeutics is committed to deliver safe, effective and affordable stem cell based products by matching customer satisfaction for "Regenerating Hope"